Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study
The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk. This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboproph...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-04, Vol.16 (7), p.1442 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 1442 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Kouvela, Marousa Livanou, Maria Effrosyni Stefanou, Dimitra T Vathiotis, Ioannis A Sarropoulou, Fotini Grammoustianou, Maria Dimakakos, Evangelos Syrigos, Nikolaos |
| description | The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk.
This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested.
In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (
= 0.26 and
= 0.32, respectively).
Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE. |
| doi_str_mv | 10.3390/cancers16071442 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3038440299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A790017721</galeid><sourcerecordid>A790017721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-ea76cb1a7191e6c36bdcc7be1ed72678494f315977cb603151d8bd209b2a26243</originalsourceid><addsrcrecordid>eNptkstu1TAQhi0EolXpmh2yxIZF0_qS2gm7o6hQpCO14hzWkeNMTlwSO9hOS3geHhT3xqViLMuj0ff_mrEGodeUHHNekhOtrAYfqCCS5jl7hvYZkSwTosyf_5XvocMQrkgKzqkU8iXa44WgKYp99POs64xWesHKtnijOogLdh3eGvtDTcobi7e9d2PjJu-mfhnUdxNwqq5nu8PVXQf4UkUDNgZ8Y2KPz82ufxRBuoPR-LMJX9_jFb70Lkygo7mGI3zRBPDXSeusGo7wxtjdAFmVnJJn5XrnI97EuV1eoRedGgIcPrwH6MuHs211nq0vPn6qVutM80LGDJQUuqFK0pKC0Fw0rdayAQqtZEIWeZl3nJ6WUupGkJTRtmhaRsqGKSZYzg_Qu3vfNOu3GUKsRxM0DIOy4OZQc8KLPCesLBP69gl65Waf5rijJD-VlIo_1E4NUBvbueiVvjWtV7IkhErJaKKO_0Ol08JotLPQmVT_R3ByL9DpO4OHrp68GZVfakrq29Won6xGUrx5aHduRmh_84-LwH8BtNO1ew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3037357116</pqid></control><display><type>article</type><title>Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kouvela, Marousa ; Livanou, Maria Effrosyni ; Stefanou, Dimitra T ; Vathiotis, Ioannis A ; Sarropoulou, Fotini ; Grammoustianou, Maria ; Dimakakos, Evangelos ; Syrigos, Nikolaos</creator><creatorcontrib>Kouvela, Marousa ; Livanou, Maria Effrosyni ; Stefanou, Dimitra T ; Vathiotis, Ioannis A ; Sarropoulou, Fotini ; Grammoustianou, Maria ; Dimakakos, Evangelos ; Syrigos, Nikolaos</creatorcontrib><description>The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk.
This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested.
In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (
= 0.26 and
= 0.32, respectively).
Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16071442</identifier><identifier>PMID: 38611118</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenocarcinoma ; Anticoagulants ; Blood ; Blood clot ; Blood platelets ; Cancer ; Cancer patients ; Cancer therapies ; Cardiovascular disease ; Care and treatment ; Chemotherapy ; Clinical medicine ; Cohort analysis ; Disease prevention ; Drug dosages ; Drug therapy ; Embolism ; Health aspects ; Hemoglobin ; Heparin ; Histology ; Immunotherapy ; Lung cancer ; Molecular weight ; Morbidity ; Mortality ; Oncology ; Oncology, Experimental ; Patient compliance ; Patients ; Pulmonary embolism ; Respiratory agents ; Risk factors ; Thromboembolism ; Thrombosis ; Tumors</subject><ispartof>Cancers, 2024-04, Vol.16 (7), p.1442</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c387t-ea76cb1a7191e6c36bdcc7be1ed72678494f315977cb603151d8bd209b2a26243</cites><orcidid>0000-0003-3002-9851 ; 0000-0003-1709-5010 ; 0000-0002-1772-5986 ; 0000-0002-2309-1852 ; 0000-0002-3627-6290 ; 0000-0001-8082-594X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38611118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kouvela, Marousa</creatorcontrib><creatorcontrib>Livanou, Maria Effrosyni</creatorcontrib><creatorcontrib>Stefanou, Dimitra T</creatorcontrib><creatorcontrib>Vathiotis, Ioannis A</creatorcontrib><creatorcontrib>Sarropoulou, Fotini</creatorcontrib><creatorcontrib>Grammoustianou, Maria</creatorcontrib><creatorcontrib>Dimakakos, Evangelos</creatorcontrib><creatorcontrib>Syrigos, Nikolaos</creatorcontrib><title>Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk.
This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested.
In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (
= 0.26 and
= 0.32, respectively).
Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.</description><subject>Adenocarcinoma</subject><subject>Anticoagulants</subject><subject>Blood</subject><subject>Blood clot</subject><subject>Blood platelets</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Cohort analysis</subject><subject>Disease prevention</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Embolism</subject><subject>Health aspects</subject><subject>Hemoglobin</subject><subject>Heparin</subject><subject>Histology</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Molecular weight</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>Pulmonary embolism</subject><subject>Respiratory agents</subject><subject>Risk factors</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkstu1TAQhi0EolXpmh2yxIZF0_qS2gm7o6hQpCO14hzWkeNMTlwSO9hOS3geHhT3xqViLMuj0ff_mrEGodeUHHNekhOtrAYfqCCS5jl7hvYZkSwTosyf_5XvocMQrkgKzqkU8iXa44WgKYp99POs64xWesHKtnijOogLdh3eGvtDTcobi7e9d2PjJu-mfhnUdxNwqq5nu8PVXQf4UkUDNgZ8Y2KPz82ufxRBuoPR-LMJX9_jFb70Lkygo7mGI3zRBPDXSeusGo7wxtjdAFmVnJJn5XrnI97EuV1eoRedGgIcPrwH6MuHs211nq0vPn6qVutM80LGDJQUuqFK0pKC0Fw0rdayAQqtZEIWeZl3nJ6WUupGkJTRtmhaRsqGKSZYzg_Qu3vfNOu3GUKsRxM0DIOy4OZQc8KLPCesLBP69gl65Waf5rijJD-VlIo_1E4NUBvbueiVvjWtV7IkhErJaKKO_0Ol08JotLPQmVT_R3ByL9DpO4OHrp68GZVfakrq29Won6xGUrx5aHduRmh_84-LwH8BtNO1ew</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Kouvela, Marousa</creator><creator>Livanou, Maria Effrosyni</creator><creator>Stefanou, Dimitra T</creator><creator>Vathiotis, Ioannis A</creator><creator>Sarropoulou, Fotini</creator><creator>Grammoustianou, Maria</creator><creator>Dimakakos, Evangelos</creator><creator>Syrigos, Nikolaos</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3002-9851</orcidid><orcidid>https://orcid.org/0000-0003-1709-5010</orcidid><orcidid>https://orcid.org/0000-0002-1772-5986</orcidid><orcidid>https://orcid.org/0000-0002-2309-1852</orcidid><orcidid>https://orcid.org/0000-0002-3627-6290</orcidid><orcidid>https://orcid.org/0000-0001-8082-594X</orcidid></search><sort><creationdate>20240401</creationdate><title>Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study</title><author>Kouvela, Marousa ; Livanou, Maria Effrosyni ; Stefanou, Dimitra T ; Vathiotis, Ioannis A ; Sarropoulou, Fotini ; Grammoustianou, Maria ; Dimakakos, Evangelos ; Syrigos, Nikolaos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-ea76cb1a7191e6c36bdcc7be1ed72678494f315977cb603151d8bd209b2a26243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adenocarcinoma</topic><topic>Anticoagulants</topic><topic>Blood</topic><topic>Blood clot</topic><topic>Blood platelets</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Cohort analysis</topic><topic>Disease prevention</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Embolism</topic><topic>Health aspects</topic><topic>Hemoglobin</topic><topic>Heparin</topic><topic>Histology</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Molecular weight</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>Pulmonary embolism</topic><topic>Respiratory agents</topic><topic>Risk factors</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kouvela, Marousa</creatorcontrib><creatorcontrib>Livanou, Maria Effrosyni</creatorcontrib><creatorcontrib>Stefanou, Dimitra T</creatorcontrib><creatorcontrib>Vathiotis, Ioannis A</creatorcontrib><creatorcontrib>Sarropoulou, Fotini</creatorcontrib><creatorcontrib>Grammoustianou, Maria</creatorcontrib><creatorcontrib>Dimakakos, Evangelos</creatorcontrib><creatorcontrib>Syrigos, Nikolaos</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kouvela, Marousa</au><au>Livanou, Maria Effrosyni</au><au>Stefanou, Dimitra T</au><au>Vathiotis, Ioannis A</au><au>Sarropoulou, Fotini</au><au>Grammoustianou, Maria</au><au>Dimakakos, Evangelos</au><au>Syrigos, Nikolaos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>16</volume><issue>7</issue><spage>1442</spage><pages>1442-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk.
This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested.
In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (
= 0.26 and
= 0.32, respectively).
Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38611118</pmid><doi>10.3390/cancers16071442</doi><orcidid>https://orcid.org/0000-0003-3002-9851</orcidid><orcidid>https://orcid.org/0000-0003-1709-5010</orcidid><orcidid>https://orcid.org/0000-0002-1772-5986</orcidid><orcidid>https://orcid.org/0000-0002-2309-1852</orcidid><orcidid>https://orcid.org/0000-0002-3627-6290</orcidid><orcidid>https://orcid.org/0000-0001-8082-594X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-04, Vol.16 (7), p.1442 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3038440299 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adenocarcinoma Anticoagulants Blood Blood clot Blood platelets Cancer Cancer patients Cancer therapies Cardiovascular disease Care and treatment Chemotherapy Clinical medicine Cohort analysis Disease prevention Drug dosages Drug therapy Embolism Health aspects Hemoglobin Heparin Histology Immunotherapy Lung cancer Molecular weight Morbidity Mortality Oncology Oncology, Experimental Patient compliance Patients Pulmonary embolism Respiratory agents Risk factors Thromboembolism Thrombosis Tumors |
| title | Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A04%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Tinzaparin%20Thromboprophylaxis%20in%20Lung%20Cancer%20Patients%20with%20High%20Thromboembolic%20Risk:%20A%20Prospective,%20Observational,%20Single-Center%20Cohort%20Study&rft.jtitle=Cancers&rft.au=Kouvela,%20Marousa&rft.date=2024-04-01&rft.volume=16&rft.issue=7&rft.spage=1442&rft.pages=1442-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16071442&rft_dat=%3Cgale_proqu%3EA790017721%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3037357116&rft_id=info:pmid/38611118&rft_galeid=A790017721&rfr_iscdi=true |